RxDoctor Payments Data

Jenna Raju, PA

Medical · Woodstock, ILNPI 1669883971

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.6% of the total across 365 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 31.3% of the total.

$5,283in general payments, 2019–2025

Across 365 payments — averaging $14.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Sanofi$660
  • Lilly USA, LLC$514
  • Amgen$406
  • Regeneron Healthcare Solutions, Inc.$346
  • Johnson & Johnson$331
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$5,04996%
  • Education$2344%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,283 in reported general payments places this provider in the 85th percentile of 449 medical providers in Illinois.

See all medical providers in Illinois

Medicare billing

Part B allowed, 2024
$109,839
Medicare patients
565
Services billed
1,974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab45$185,210
Taltz AutoinjectorIxekizumab12$83,341
OpzeluraRuxolitinib Phosphate13$26,463
Clobetasol Propionate134$9,247
Pimecrolimus11$4,933
Fluorouracil14$1,904
Ketoconazole91$1,739
Doxycycline Hyclate47$1,561
Triamcinolone Acetonide108$1,174
Metronidazole22$1,146
Alclometasone Dipropionate24$940
Ampicillin Trihydrate18$908
Clindamycin Phosphate25$763
CiclopiroxCiclopirox Olamine19$562
Mupirocin72$508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$57$26,46313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 449 medical providers in Illinois.

Other medical in Woodstock

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →